Domainex is a Europe's fastest growing drug discovery CRO. It serves pharmaceutical, biotechnology, academic and patient foundations globally. Domainex’s drug discovery service business was established in 2001 and since that time has continued to expand to serve a wider range of international clients including UCB, FORMA Therapeutics, St George’s University, and The Institute of Cancer Research. Our expertise and commitment to providing high quality services has resulted in a strong success record in drug discovery, delivering an average one candidate drug every year.
Domainex’s highly experienced molecular biologists, assay biologists, medicinal, computational and analytical chemists can be leveraged through our CRO services. Domainex’s focus is on providing highly efficient and well considered scientific solutions to enable successful drug discovery programmes against a wide range of drug targets. Whether your project is at an early stage of drug discovery or has already identified chemical matter, our processes have been shown to result in a 30% time-saving compared to industry standards and use less resource, allowing effective management of your own budget.
More information regarding Domainex's drug discovery services can be found by following the relevant links, including its medicinal chemistry and computational chemistry services, protein expression capabilities and cell-based and biochemical assay development offering.
Details of Domainex's drug discovery pipeline can be found by following the links below: